Bidirectional interplay between SARS-CoV-2 and autophagy.

Publication date: Jul 12, 2023

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as the causative agent of the recent COVID-19 pandemic, continues representing one of the main health concerns worldwide. Autophagy, in addition to its role in cellular homeostasis and metabolism, plays an important part for the host antiviral immunity. However, viruses including SARS-CoV-2 have evolved diverse mechanisms to not only overcome autophagy’s antiviral pressure but also manipulate its machinery in order to enhance viral replication and propagation. Here, we discuss our current knowledge on the impact that autophagy exerts on SARS-CoV-2 replication, as well as the different counteracting measures that this virus has developed to manipulate autophagy’s complex machinery. Some of the elements regarding this interplay may become future therapeutic targets in the fight against SARS-CoV-2.

Open Access PDF

Concepts Keywords
Coronavirus autophagy
Covid COVID-19
Future innate immunity
Homeostasis SARS-CoV-2
Severe therapeutic targets


Type Source Name
pathway KEGG Autophagy
disease VO Severe acute respiratory syndrome coronavirus 2
disease MESH COVID-19 pandemic
disease IDO host
disease VO Viruses
pathway KEGG Viral replication
disease IDO replication
disease MESH virus infections
drug DRUGBANK Angiotensin II
disease IDO cell
disease VO ORF
drug DRUGBANK Papain
disease VO volume
disease VO USA
disease IDO process
disease IDO site
pathway KEGG Lysosome
drug DRUGBANK Trestolone
disease MESH infection
drug DRUGBANK Sirolimus
disease MESH starvation
drug DRUGBANK Rasagiline
disease MESH sarcoma
disease MESH fibrosarcoma
drug DRUGBANK Adenosine phosphate
pathway KEGG Focal adhesion
drug DRUGBANK Phosphate ion
drug DRUGBANK Zinc
drug DRUGBANK Phosphatidylethanolamine
disease MESH repression
pathway KEGG Mitophagy
disease IDO production
pathway KEGG Endocytosis
drug DRUGBANK Spermine
drug DRUGBANK Spermidine
disease VO dose
drug DRUGBANK Ciclosporin
drug DRUGBANK Alisporivir
drug DRUGBANK Chloroquine
drug DRUGBANK Hydroxychloroquine
drug DRUGBANK Saquinavir
drug DRUGBANK Clomipramine
drug DRUGBANK Hycanthone
drug DRUGBANK Verteporfin
drug DRUGBANK Mefloquine
disease VO effective
disease MESH pneumonia
disease MESH cytokine storm
drug DRUGBANK Coenzyme M
drug DRUGBANK (S)-Des-Me-Ampa
drug DRUGBANK Carboxyamidotriazole
disease IDO pathogen
disease MESH Cancers
disease MESH liver diseases
drug DRUGBANK Guanosine
disease MESH hepatitis
drug DRUGBANK Isoxaflutole
disease IDO organism
drug DRUGBANK Sotalol
disease IDO innate immune response
disease MESH Death
disease MESH Parkinson disease
pathway KEGG Parkinson disease
disease MESH coronavirus infection
disease VO Nef
disease MESH West Nile virus infection
disease VO Gag
drug DRUGBANK Vorinostat
disease MESH inflammation
pathway KEGG Apoptosis
drug DRUGBANK Troleandomycin

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *